Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Non-Current Liabilities: 2012-2024

Historic Other Non-Current Liabilities for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $21.4 million.

  • Ptc Therapeutics' Other Non-Current Liabilities fell 88.28% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 88.28%. This contributed to the annual value of $21.4 million for FY2024, which is 40.98% down from last year.
  • Per Ptc Therapeutics' latest filing, its Other Non-Current Liabilities stood at $21.4 million for FY2024, which was down 40.98% from $36.3 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Other Non-Current Liabilities peaked at $240.4 million during FY2020, and registered a low of $21.4 million during FY2024.
  • Over the past 3 years, Ptc Therapeutics' median Other Non-Current Liabilities value was $36.3 million (recorded in 2023), while the average stood at $73.9 million.
  • Data for Ptc Therapeutics' Other Non-Current Liabilities shows a maximum YoY plummeted of 77.87% (in 2023) over the last 5 years.
  • Ptc Therapeutics' Other Non-Current Liabilities (Yearly) stood at $240.4 million in 2020, then dropped by 0.21% to $239.9 million in 2021, then crashed by 31.64% to $164.0 million in 2022, then slumped by 77.87% to $36.3 million in 2023, then plummeted by 40.98% to $21.4 million in 2024.